Aspira Pathlab & Diagnostics Ltd Fair Value
ASPIRAPATHLABLTD · Healthcare Services · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹15 | 17% ROE fading to 12% over ~10 yrs, on ₹12 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is Aspira Pathlab & Diagnostics Ltd undervalued?
We couldn't compute a reliable fair value for Aspira Pathlab & Diagnostics Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹15). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹13 (bear) to ₹15 (base) to ₹17 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Aspira Pathlab & Diagnostics Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.